Skip to main content
Log in

Rifaximin versus Other Antibiotics in the Primary Treatment and Retreatment of Bacterial Overgrowth in IBS

  • Original Paper
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Purpose

Previous studies demonstrate improvement in IBS after antibiotic therapy, with the greatest efficacy seen with the antibiotic, rifaximin. The purpose of this study was to compare the efficacy of rifaximin in both the treatment and retreatment of IBS.

Methods

A retrospective chart review was conducted on Rome I-positive IBS patients. Charts were reviewed to evaluate all antibiotic treatments (rifaximin, neomycin, doxycycline, amoxicillin/clavulanate, and ciprofloxacin), even those predating 1 July 2004. Data collection included symptoms, breath test results (pre- and post-treatment), antibiotics used, and clinical response to individual antibiotic treatments before and after rifaximin availability in the USA.

Results

Out of 98 eligible charts, 84 patients received one course of rifaximin. Fifty of these (60%) had a follow-up breath test. Among these, 31 (62%) were clinical responders and 19 (38%) were nonresponders. Of 31 responders, 25 (81%) had a normal follow-up breath test compared with only 3 of the 19 nonresponders (16%) (P < 0.001). Of participants given rifaximin, 69% (58 out of 84) had a clinical response compared with only 38% (9 out of 24) with neomycin (P < 0.01) and 44% (27 out of 61) with all non-rifaximin antibiotics (P < 0.01). Rifaximin was used as retreatment on 16 occasions, and all patients improved.

Conclusions

Rifaximin is more effective than other antibiotics in the treatment and retreatment of IBS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Drossman DA (1994) The functional gastrointestinal disorders: diagnosis, pathophysiology, and treatment. A multinational consensus. Little, Brown, Boston

    Google Scholar 

  2. Drossman DA, Whitehead WE, Camilleri M (1997) Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 112:2120–2137

    Article  PubMed  CAS  Google Scholar 

  3. Thompson WG, Heaton KW (1980) Functional bowel disorders in apparently healthy people. Gastroenterology 79:283–288

    PubMed  CAS  Google Scholar 

  4. Kumar D, Wingate DL (1985) The irritable bowel syndrome: a paroxysmal motor disorder. Lancet 2:973–977

    Article  PubMed  CAS  Google Scholar 

  5. Grundy D (2000) Mechanisms for the symptoms of irritable bowel disease—possible role of vagal afferents. In: Krammer H-J, Singer MV (eds) Neurogastroenterology from the basics to the clinics. Kluwer, Boston, pp 659–663

    Google Scholar 

  6. Silverman DHS, Munakata JA, Ennes H et al (1997) Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology 112:64–72

    Article  PubMed  CAS  Google Scholar 

  7. Whitehead WE, Crowell MD, Robinson JC et al (1992) Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut 33:825–830

    Article  PubMed  CAS  Google Scholar 

  8. Thompson WG, Longstreth GF, Drossman DA et al (1999) Functional bowel disorders and functional abdominal pain. Rome II: a multinational consensus document on functional gastrointestinal disorders. Gut 45:1143–1147

    Google Scholar 

  9. Longstreth G, Thompson G, Chey W et al (2006) Functional bowel disorders. Gastroenterology 130:1480–1491

    Article  PubMed  Google Scholar 

  10. Holt PR (1990) Diarrhea and malabsorption in the elderly. Gastroenterol Clin North Am 19:345–359

    PubMed  CAS  Google Scholar 

  11. Pimentel M, Chow EJ, Lin HC (2000) Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 95:3503–3506

    Article  PubMed  CAS  Google Scholar 

  12. Pimentel M, Chow EJ, Lin HC (2003) Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 98:412–418

    PubMed  Google Scholar 

  13. Lupascu A, Gabrielli M, Lauritano EC et al (2005) Hydrogen glucose breath test to detect bacterial overgrowth: a prevalence case–control study in irritable bowel syndrome. Aliment Pharmacol Ther 22:1157–1160

    Article  PubMed  CAS  Google Scholar 

  14. McCallum R, Schultz C, Sostarich S (2005) Evaluating the role of small intestinal bacterial overgrowth (SIBO) in diarrhea predominant irritable bowel syndrome (IBS-D) patients utilizing the glucose breath test (GBT). Gastroenterology 128:A460

    Google Scholar 

  15. Posserud I, Stotzer PO, Einar S et al (2006) Altered counts of small bowel bacteria in patients with irritable bowel syndrome. Gastroenterol 130:A739

    Google Scholar 

  16. Drude RB, Finkelman D, Davis WD et al (1980) Malabsorption in jejunal diverticulosis treated with resection of the diverticula. Dig Dis Sci 25:802–806

    Article  PubMed  Google Scholar 

  17. Soudah HC, Hasier WL, Owyang C (1991) Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 325:1461–1467

    Article  PubMed  CAS  Google Scholar 

  18. Di Stefano M, Malservisi S, Veneto G et al (2000) Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 14:551–556

    Article  PubMed  CAS  Google Scholar 

  19. Attar A, Flourie B, Rambaud JC et al (1999) Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 117:794–797

    Article  PubMed  CAS  Google Scholar 

  20. Scarpignato C, Pelosini I (2005) Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 51:S36–S66

    Article  CAS  Google Scholar 

  21. Sharara AI, Aoun E, Abdul-Baki H et al (2006) A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 101:326–333

    Article  PubMed  CAS  Google Scholar 

  22. Pimentel M, Park S, Kong Y, Kane SV (2006) Rifaximin, a non-absorbable antibiotic improves the symptoms of irritable bowel syndrome: a double-blind randomized controlled study. Ann Intern Med 145:557–563

    PubMed  Google Scholar 

  23. Nucera G, Gabrielli M, Lupascu A et al (2005) Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther 21:1391–1395

    Article  PubMed  CAS  Google Scholar 

  24. Simren M, Ringstrom G, Agerforz P et al (2003) Small intestinal bacterial overgrowth is not of major importance in irritable bowel syndrome. Gastroenterology 124:A163

    Article  Google Scholar 

  25. Robson KM, Kakullavarapu J, Lembo T (2003) Bacterial overgrowth and irritable bowel syndrome: a look at prevalence, symptoms and quality of life. Am J Gastroenterol 98:S271

    Article  Google Scholar 

  26. Singh VV, Toskes PP (2004) Small bowel bacterial overgrowth: presentation, diagnosis, and treatment. Curr Treat Options Gastroenterol 7:19–28

    Article  PubMed  Google Scholar 

  27. Hoover W, Gerlach E, Hoban D et al (1993) Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diag Microbiol Infect Dis 16:111–118

    Article  CAS  Google Scholar 

  28. Gillis JC, Brogden RN (1995) Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 49:467–484

    Article  PubMed  CAS  Google Scholar 

  29. DuPont HL, Jiang ZD, Okhuysen PC et al (2005) A randomized, double-blind, placebo-controlled trial of rifaximin to prevent traveler’s diarrhea. Ann Intern Med 142:805–812

    PubMed  CAS  Google Scholar 

  30. Mas A, Rodes J, Sunyer L et al (2003) Spanish association for the study of liver hepatic encephalopathy cooperative group. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double dummy, controlled clinical trial. J Hepatol 38:51–58

    Article  PubMed  CAS  Google Scholar 

  31. Gerard L, Garey KW, DuPont HL (2005) Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther 3:201–211

    Article  PubMed  CAS  Google Scholar 

  32. DuPont HL (2003) Community-acquired diarrheal disease in western countries: application of nonabsorbable oral antibiotic therapy. Adv Stud Med 3:S945–S950

    Google Scholar 

  33. Lauritano EC, Gabrielli M, Lupascu A et al (2005) Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 22:31–35

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was funded through an unrestricted investigator grant with Salix Pharmaceuticals.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mark Pimentel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, J., Lee, HR., Low, K. et al. Rifaximin versus Other Antibiotics in the Primary Treatment and Retreatment of Bacterial Overgrowth in IBS. Dig Dis Sci 53, 169–174 (2008). https://doi.org/10.1007/s10620-007-9839-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-007-9839-8

Keywords

Navigation